SEC Form 4 · accession 0000874015-18-000002
IONIS PHARMACEUTICALS INC · IONS
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
C Frank Bennett
Officer — SVP, Antisense Research
Period of report
Jan 1, 2018
Accepted (ET)
Jan 2, 2018 · 8:45 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0000874015
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF1 | Jan 1, 2018 | J | 106 | $42.755 | A | 15,147 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Employee Stock Option (right to buy)F2 | $49.25 | Jan 2, 2018 | A | 54,619 | A | Jan 2, 2019 | Jan 1, 2025 | Common Stock | 54,619 | 54,619 | D |
Explanation of responses
- F1Reporting 106 shares acquired under the Ionis Pharmaceuticals, Inc. Amended and Restated 2000 Employee Stock Purchase Plan on January 1, 2018. These 106 shares may not be sold until July 2, 2018.
- F2Grant of 1/2/2018 to reporting person of stock options under the Ionis Pharmaceuticals, Inc. 2011 Equity Incentive Plan. 25% of the shares subject to the option vest and become exercisable on 1/2/2019. Thereafter, the remaining shares subject to the option vest and become exercisable in 36 equal monthly installments, at the rate of 13,655 shares per year. Following this transaction, the option was exercisable as to 0 on 1/2/2018.